Viking Therapeutics (VKTX) Interest & Investment Income (2014 - 2026)

Viking Therapeutics has reported Interest & Investment Income for 12 years, with the latest figure at -$299000.0 in Q2 2026.

• Quarterly Interest & Investment Income fell 1250.0% year-over-year to -$299000.0 in Q2 2026, while the trailing twelve-month figure through Jun 2026 was -$1.0 million (down 145.51% YoY) and the FY2025 annual result came in at $1.1 million, up 746.82% from the prior year.
• Interest & Investment Income advanced to -$299000.0 in Q2 2026 per VKTX's latest filing, from -$1.2 million in the prior quarter.
• Over five years, Interest & Investment Income peaked at $3.9 million in Q3 2024 and troughed at -$2.3 million in Q4 2024.
• A 5-year average of -$8722.2 and a median of $8000.0 in 2025 frame the typical range for Interest & Investment Income.
• The sharpest annual moves came in 2022 and 2024: Interest & Investment Income tumbled 1686.0% in 2022, then surged 1665.61% in 2024.
• Over 5 years, Interest & Investment Income stood at $518000.0 in 2022, then decreased by 15.64% to $437000.0 in 2023, then tumbled by 615.33% to -$2.3 million in 2024, then surged by 99.56% to -$10000.0 in 2025, then sank by 2890.0% to -$299000.0 in 2026.
• According to Business Quant data, Interest & Investment Income over the past three periods registered -$299000.0, -$1.2 million, and -$10000.0 for Q2 2026, Q1 2026, and Q4 2025 respectively.